CincyTech-backed Eikonoklastes Therapeutics clears FDA hurdle for first-in-class ALS treatment

A Cincinnati-based biotech startup developing a first-in-class treatment for ALS is celebrating a key regulatory milestone, roughly two years after landing its first tranche of funding from Uptown-based investment firm CincyTech.

Eikonoklastes Therapeutics, a preclinical biotech company developing new drugs for neurodegenerative diseases and cancers, this week received U.S. Food and Drug Administration orphan drug designation for its ET-101 program. According to the FDA, orphan drug designation supports drugs that aim to prevent, diagnose or treat a rare diseases or conditions.

Click here to read the complete story.

Story excerpt provided by Cincy Inno.

Written by Liz Engel.

Originally published November 9, 2022.